Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Antibody-drug conjugates (ADCs) are altering how remedy is delivered for sufferers with breast most cancers, in response to Dr. Paolo Tarantino. In contrast...
Advancing novel therapies into earlier remedy strains could assist delay the necessity for chemotherapy and enhance high quality of life for sufferers. Furthermore,...
